Zacks Investment Research cut shares of aTyr Pharma, Inc. (NASDAQ:LIFE) from a buy rating to a hold rating in a research note issued to investors on Wednesday morning. Zacks Investment Research currently has $3.25 target price on the biotechnology company’s stock.

According to Zacks, “aTyr Pharma, Inc. is a bio-therapeutics company. The Company is involved in the discovery and development of medicines for severe, rare diseases of physiological modulators. aTyr Pharma, Inc. is a based in SAN DIEGO, United States. “

A number of other equities research analysts also recently issued reports on LIFE. BMO Capital Markets reissued a hold rating on shares of aTyr Pharma in a report on Wednesday, May 24th. ValuEngine raised shares of aTyr Pharma from a sell rating to a hold rating in a report on Saturday, July 8th. One analyst has rated the stock with a sell rating and four have assigned a hold rating to the company. The stock has a consensus rating of Hold and an average price target of $3.53.

aTyr Pharma (LIFE) opened at 3.05 on Wednesday. aTyr Pharma has a 12-month low of $2.10 and a 12-month high of $4.45. The firm has a 50-day moving average of $3.10 and a 200 day moving average of $3.33. The company’s market capitalization is $72.71 million.

aTyr Pharma (NASDAQ:LIFE) last announced its quarterly earnings results on Monday, August 14th. The biotechnology company reported ($0.51) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.06. Analysts expect that aTyr Pharma will post ($2.18) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece of content was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another site, it was stolen and reposted in violation of US and international copyright law. The original version of this piece of content can be viewed at

A hedge fund recently raised its stake in aTyr Pharma stock. Renaissance Technologies LLC increased its position in shares of aTyr Pharma, Inc. (NASDAQ:LIFE) by 1.8% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 38,800 shares of the biotechnology company’s stock after buying an additional 700 shares during the period. Renaissance Technologies LLC owned 0.16% of aTyr Pharma worth $136,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 46.66% of the company’s stock.

About aTyr Pharma

aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.

Get a free copy of the Zacks research report on aTyr Pharma (LIFE)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Stock Ratings for aTyr Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma Inc. and related stocks with our FREE daily email newsletter.